Sold as Pmb 400, Pmb 200, Milprem-400, Milprem-200. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Estrogens, Conjugated; Meprobamate (sold as Pmb 400, Pmb 200, Milprem-400 and others), first approved May 31, 1957, with 0 new uses approved and 0 published complete response letters.
| May 31, 1957 | Pmb 400, Pmb 200NDA 10971 · New combination | Wyeth Ayerst | 7 | Discontinued |
| — | Milprem-400, Milprem-200NDA 11045 | Medpointe Pharm Hlc | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
